
Dynavax Technologies (DVAX) Stock Forecast & Price Target
Dynavax Technologies (DVAX) Analyst Ratings
Bulls say
Dynavax Technologies Corp demonstrates a strong positive outlook due to its promising vaccine candidates, particularly the shingles vaccine, which has shown vaccine response rates comparable to that of Shingrix while exhibiting significantly better tolerability. The encouraging results regarding immunogenicity and tolerability align well with management's expectations, further solidifying the company’s position in the biopharmaceutical market. Additionally, the robust revenue generation from its existing products, CpG 1018 and HEPLISAV-B, underscores the company's financial stability and growth potential in the vaccination sector.
Bears say
Dynavax Technologies faces a negative outlook primarily due to the high risk associated with its clinical candidates, which may fail to demonstrate efficacy or pose safety concerns that could hinder regulatory approval and commercialization. Additionally, the company may encounter challenges in effectively commercializing its products due to adverse market conditions, intense competition, and potential difficulties in securing favorable partnership agreements. Furthermore, litigation risks could further complicate Dynavax's ability to navigate the competitive landscape and achieve successful product launches.
This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.
Dynavax Technologies (DVAX) Analyst Forecast & Price Prediction
Start investing in Dynavax Technologies (DVAX)
Order type
Buy in
Order amount
Est. shares
0 shares